{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T12:38:48Z","timestamp":1794573528408,"version":"4.9.1"},"reference-count":130,"publisher":"Informa UK Limited","issue":"8","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2025,5,24]]},"DOI":"10.1080\/14656566.2025.2496424","type":"journal-article","created":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T16:13:33Z","timestamp":1746375213000},"page":"939-952","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":23,"title":["Beyond the injection: delivery systems reshaping retinal disease management"],"prefix":"10.1080","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1225-154X","authenticated-orcid":false,"given":"Lucas W.","family":"Rowe","sequence":"first","affiliation":[{"name":"Indiana University School of Medicine","place":["Indianapolis, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Akotoye","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine","place":["Indianapolis, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alon","family":"Harris","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5557-6777","authenticated-orcid":false,"given":"Thomas A.","family":"Ciulla","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine","place":["Indianapolis, USA"]},{"name":"Midwest Eye Institute","place":["Indianapolis, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,5,11]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.11.018"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2018.01.006"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2019.05.017"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2022.03.021"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/2474126420960896"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114342"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-018-0021-7"},{"issue":"24","key":"e_1_3_4_10_1","first-page":"00029","article-title":"Biosimilars of anti-vascular endothelial growth factor for ophthalmic diseases: a review","volume":"0039","author":"Bressler NM","year":"2024","unstructured":"Bressler NM, Kaiser PK, Do DV, et al. Biosimilars of anti-vascular endothelial growth factor for ophthalmic diseases: a review. Surv Ophthalmol. 2024;S0039\u20136257(24):00029\u20138.","journal-title":"Surv Ophthalmol"},{"key":"e_1_3_4_11_1","unstructured":"Research C for DE and. FDA approves first interchangeable biosimilars to Eylea to treat macular degeneration and other eye conditions. FDA[Internet]. 2024 [cited 2024 Jun 2]."},{"key":"e_1_3_4_12_1","unstructured":"Ahzantive receives FDA approval as new eylea biosimilar [internet]. Center for Biosimilars. 2024 [cited 2024 Jul 2]. Available from: https:\/\/www.centerforbiosimilars.com\/view\/ahzantive-receives-fda-approval-as-new-eylea-biosimilar"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2008.05.036"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2012.03.047"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000002566"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14020265"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/aos.15242"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.07.060"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(13)70145-1"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26020556"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.04.017"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.06.028"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.11.011"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.04.017"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2022.04.028"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.09.006"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.03.020"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00063-1"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.3928\/23258160-20220516-01"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.13.11.14"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00018-6"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2023.12.026"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00010-1"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2021.100076"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2024.01.029"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-024-00525-9"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-023-02553-5"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2023.02.001"},{"key":"e_1_3_4_39_1","unstructured":"Opthea completes enrollment in pivotal phase 3 clinical program with sozinibercept in wet AMD - Opthea limited inc [Internet]. [cited 2024 Jun 2]. Available from: https:\/\/ir.opthea.com\/news-releases\/news-release-details\/opthea-completes-enrollment-pivotal-phase-3-clinical-program\/"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.03.036"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2022.03.005"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2290"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2023.02.024"},{"key":"e_1_3_4_44_1","article-title":"Port delivery system with ranibizumab in patients with diabetic macular edema: primary analysis results of the phase 3 pagoda trial","author":"Khanani AM","year":"2023","unstructured":"Khanani AM. Port delivery system with ranibizumab in patients with diabetic macular edema: primary analysis results of the phase 3 pagoda trial. Presented At: Bascom Palmer Eye Inst Angiogenesis, Exudation, and Degeneration; 2023 Feb 10\u201311; Virtual.","journal-title":"Presented At: Bascom Palmer Eye Inst Angiogenesis, Exudation, and Degeneration"},{"key":"e_1_3_4_45_1","article-title":"Port delivery system with ranibizumab in patients with diabetic retinopathy: primary analysis results of the phase 3 pavilion trial","author":"Pieramici D","year":"2023","unstructured":"Pieramici D. Port delivery system with ranibizumab in patients with diabetic retinopathy: primary analysis results of the phase 3 pavilion trial. Presented At: Bascom Palmer Eye Inst Angiogenesis, Exudation, and Degeneration. 2023 Feb 10\u201311; Virtual.","journal-title":"Presented At: Bascom Palmer Eye Inst Angiogenesis, Exudation, and Degeneration"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-023-00446-z"},{"key":"e_1_3_4_47_1","unstructured":"Genentech: press releases | Tuesday Feb 4. 2025 [Internet]. [cited 2025 Feb 23]. Available from: https:\/\/www.gene.com\/media\/press-releases\/15050\/2025-02-04\/fda-approves-genentechs-susvimo-as-the-f"},{"issue":"7","key":"e_1_3_4_48_1","first-page":"6232","article-title":"Port delivery system with ranibizumab (PDS) stabilizes retinal nonperfusion and macular leakage: results from pagoda and pavilion phase 3 trials in diabetic macular edema (DME) and diabetic retinopathy (DR)","volume":"65","author":"Wirthlin R","year":"2024","unstructured":"Wirthlin R, Gill M, Howard D, et al. Port delivery system with ranibizumab (PDS) stabilizes retinal nonperfusion and macular leakage: results from pagoda and pavilion phase 3 trials in diabetic macular edema (DME) and diabetic retinopathy (DR). Invest Ophthalmol Visual Sci. 2024;65(7):6232.","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"e_1_3_4_49_1","unstructured":"Genentech. Press releases |. Thursday. 2024 [Internet]. [Jul 18 [cited 2024 Nov 13]. Available from: https:\/\/www.gene.com\/media\/press-releases\/15034\/2024-07-18\/new-data-for-genentechs-susvimo-demonstr"},{"key":"e_1_3_4_50_1","unstructured":"Study details | a study assessing corneal endothelial cells in participants with neovascular age-related macular Degeneration(nAMD) treated with the port delivery system with ranibizumab (PDS) | ClinicalTrials.Gov [Internet]. [cited 2024 Nov 18]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT04853251"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.4103\/0974-620X.200692"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.787644"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-5285"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/aos.12020"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-017-0332-x"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-023-00662-8"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13050701"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.02.021"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.11.034"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.04.001"},{"key":"e_1_3_4_61_1","unstructured":"Study details | a study of intravitreal ILUVIEN\u00ae implant as baseline therapy in patients with early diabetic macular edema (DME) | ClinicalTrials.Gov [Internet]. [cited 2024 Nov 18]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT04469595"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0740"},{"issue":"7","key":"e_1_3_4_63_1","first-page":"4401","article-title":"The DAVIO 2 trial: a phase 2, randomized, double-masked, controlled multicenter study of EYP-1901 vs aflibercept in previously treated wet age-related macular degeneration","volume":"65","author":"Eichenbaum DA","year":"2024","unstructured":"Eichenbaum DA, Hershberger V, Patel SS, et al. The DAVIO 2 trial: a phase 2, randomized, double-masked, controlled multicenter study of EYP-1901 vs aflibercept in previously treated wet age-related macular degeneration. Invest Ophthalmol Visual Sci. 2024;65(7):4401.","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"e_1_3_4_64_1","unstructured":"EyePoint pharmaceuticals announces first patient dosed in global phase 3 LUGANO clinical trial of DURAVYUTM for the treatment of wet age-related macular degeneration | EyePoint pharmaceuticals [Internet]. [cited 2024 Nov 11]. Available from: https:\/\/investors.eyepointpharma.com\/news-releases\/news-release-details\/eyepoint-pharmaceuticals-announces-first-patient-dosed-global"},{"key":"e_1_3_4_65_1","unstructured":"EyePoint announces first patient dosed in second global phase 3 LUCIA clinical trial of DURAVYUTM for the treatment of wet age-related macular degeneration | EyePoint pharmaceuticals [Internet]. [cited 2025 Feb 23]. Available from: https:\/\/investors.eyepointpharma.com\/news-releases\/news-release-details\/eyepoint-announces-first-patient-dosed-second-global-phase-3"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2022.2052042"},{"issue":"9","key":"e_1_3_4_67_1","first-page":"211","article-title":"KSI-301: an anti-VEGF antibody biopolymer conjugate with extended half-life for treatment of neovascular retinal diseases","volume":"59","author":"Liang hong","year":"2018","unstructured":"Lianghong, Huang X, Ngo W, et al. KSI-301: an anti-VEGF antibody biopolymer conjugate with extended half-life for treatment of neovascular retinal diseases. Invest Ophthalmol Visual Sci. 2018;59(9):211.","journal-title":"Invest Ophthalmol Visual Sci"},{"issue":"7","key":"e_1_3_4_68_1","first-page":"3122","article-title":"Efficacy, durability and safety of KSI-301 antibody biopolymer conjugate in wet AMD \u2013 year 1 primary endpoint results from the pivotal DAZZLE study","volume":"63","author":"Regillo C","year":"2022","unstructured":"Regillo C, Ehrlich JS, Janer D, et al. Efficacy, durability and safety of KSI-301 antibody biopolymer conjugate in wet AMD \u2013 year 1 primary endpoint results from the pivotal DAZZLE study. Invest Ophthalmol Visual Sci. 2022;63(7):3122.","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"e_1_3_4_69_1","volume-title":"56th Annual Scientific Meeting of the Retina Society","author":"Busbee B","year":"2023","unstructured":"Busbee B. Tarcocimab tedromer (KSI-301) 5 mg for the treatment of wAMD: one-year primary efficacy and safety outcomes of the phase 3 DAYLIGHT study. In: 56th Annual Scientific Meeting of the Retina Society; New York (NY); 2023."},{"issue":"7","key":"e_1_3_4_70_1","first-page":"1773","article-title":"Tarcocimab tedromer (KSI-301) 5mg: outcomes of the phase 3 GLOW study in patients with non-proliferative diabetic retinopathy","volume":"65","author":"Wong RW","year":"2024","unstructured":"Wong RW, Janer D, Zawadzki R, et al. Tarcocimab tedromer (KSI-301) 5mg: outcomes of the phase 3 GLOW study in patients with non-proliferative diabetic retinopathy. Invest Ophthalmol Visual Sci. 2024;65(7):1773.","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"e_1_3_4_71_1","unstructured":"Kodiak sciences announces treatment of first patients in phase 3 GLOW2 study of tarcocimab tedromer in diabetic retinopathy | kodiak sciences inc. [Internet]. [cited 2024 Nov 3]. Available from: https:\/\/ir.kodiak.com\/news-releases\/news-release-details\/kodiak-sciences-announces-treatment-first-patients-phase-3-glow2\/"},{"issue":"8","key":"e_1_3_4_72_1","first-page":"2215","article-title":"Biological benefits of KSI-501: novel bispecific anti-inflammatory and anti-angiogenic therapy for the treatment of both retinal vascular and inflammatory diseases","volume":"64","author":"Williams K","year":"2023","unstructured":"Williams K, Rodriguez M, Fischer W-N, et al. Biological benefits of KSI-501: novel bispecific anti-inflammatory and anti-angiogenic therapy for the treatment of both retinal vascular and inflammatory diseases. Invest Ophthalmol Visual Sci. 2023;64(8):2215.","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1177\/2041731418768285"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2019.05.037"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2020.07.031"},{"issue":"7","key":"e_1_3_4_76_1","first-page":"297","article-title":"A safety and pharmacokinetic study of a novel hydrogel-based Axitinib Intravitreal implant (OTX-TKI) in non-human primates","volume":"63","author":"Kahn E","year":"2022","unstructured":"Kahn E, Patel C, Priem M, et al. A safety and pharmacokinetic study of a novel hydrogel-based Axitinib Intravitreal implant (OTX-TKI) in non-human primates. Invest Ophthalmol Visual Sci. 2022;63(7):297\u2013F0100.","journal-title":"Invest Ophthalmol Visual Sci"},{"issue":"8","key":"e_1_3_4_77_1","first-page":"936","article-title":"U.S. Phase 1 study of intravitreal axitinib implant (OTX-TKI) for neovascular age-related macular degeneration","volume":"64","author":"Moshfeghi AA","year":"2023","unstructured":"Moshfeghi AA, Khanani AM, Eichenbaum DA, et al. U.S. Phase 1 study of intravitreal axitinib implant (OTX-TKI) for neovascular age-related macular degeneration. Invest Ophthalmol Visual Sci. 2023;64(8):936.","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"e_1_3_4_78_1","unstructured":"Ocular TherapeutixTM announces accelerated timelines for SOL-1 registrational trial of AXPAXLITM in wet AMD | ocular therapeutix inc. [Internet]. [cited 2024 Nov 13]. Available from: https:\/\/investors.ocutx.com\/news-releases\/news-release-details\/ocular-therapeutixtm-announces-accelerated-timelines-sol-1\/"},{"key":"e_1_3_4_79_1","unstructured":"Inc OT. Ocular TherapeutixTM announces first patients enrolled in phase 3 SOL-R wet AMD study [internet]. GlobeNewswire news room. 2024 [cited 2024 Nov 3]. Available from: https:\/\/www.globenewswire.com\/news-release\/2024\/07\/30\/2920887\/0\/en\/Ocular-Therapeutix-Announces-First-Patients-Enrolled-in-Phase-3-SOL-R-Wet-AMD-Study.html"},{"issue":"5","key":"e_1_3_4_80_1","first-page":"2543","article-title":"In vivo transfer of a reporter gene to the retina mediated by an adenoviral vector","volume":"35","author":"Li T","year":"1994","unstructured":"Li T, Adamian M, Roof DJ, et al. In vivo transfer of a reporter gene to the retina mediated by an adenoviral vector. Invest Ophthalmol Vis Sci. 1994;35(5):2543\u20132549.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_4_81_1","unstructured":"Commissioner O of the. FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss [internet]. FDA. FDA. 2020 [cited 2024 Nov 3]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-novel-gene-therapy-treat-patients-rare-form-inherited-vision-loss"},{"key":"e_1_3_4_82_1","unstructured":"Toronto U of. English: figure 1. Schematic overview of how viruses (i.e. adenovirus) can be used to deliver recombinant genetic material to neurons or other cell types within the nervous system. Steps include viral binding to cell membrane endosomal packaging and breakdown delivery and integration of vector into host DNA and ending with the expression of the desired protein. [Internet]. 2022 [cited 2024 Jan 31]. Available from: https:\/\/commons.wikimedia.org\/wiki\/File:Viral_mediated_delivery_of_genes_to_neurons_1.jpg"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1159\/000479157"},{"key":"e_1_3_4_84_1","unstructured":"Inc 4D molecular therapeutics. 4DMT receives FDA regenerative medicine advanced therapy (RMAT) designation for 4D\u2013150 genetic medicine for intravitreal treatment of wet AMD the first RMAT designation in wet AMD [internet]. GlobeNewswire news room. 2023 [cited 2024 Jan 18]. Available from: https:\/\/www.globenewswire.com\/news-release\/2023\/12\/21\/2799961\/0\/en\/4DMT-Receives-FDA-Regenerative-Medicine-Advanced-Therapy-RMAT-Designation-for-4D-150-Genetic-Medicine-for-Intravitreal-Treatment-of-Wet-AMD-the-First-RMAT-Designation-in-Wet-AMD.html"},{"issue":"8","key":"e_1_3_4_85_1","first-page":"5055","article-title":"Interim results for the phase 1\/2 PRISM trial evaluating 4D\u2013150, a dual-transgene intravitreal genetic medicine in individuals with neovascular (wet) age-related macular degeneration","volume":"64","author":"Khanani AM","year":"2023","unstructured":"Khanani AM, Hershberger VS, Kay CN, et al. Interim results for the phase 1\/2 PRISM trial evaluating 4D\u2013150, a dual-transgene intravitreal genetic medicine in individuals with neovascular (wet) age-related macular degeneration. Invest Ophthalmol Visual Sci. 2023;64(8):5055.","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"e_1_3_4_86_1","unstructured":"4DMT presents positive interim data from randomized phase 2 PRISM clinical trial of intravitreal 4D\u2013150 demonstrating favorable tolerability & clinical activity in wet AMD | 4D molecular therapeutics [Internet]. [cited 2024 Feb 4]. Available from: https:\/\/ir.4dmoleculartherapeutics.com\/news-releases\/news-release-details\/4dmt-presents-positive-interim-data-randomized-phase-2-prism\/"},{"key":"e_1_3_4_87_1","unstructured":"4DMT presents positive 52-week results from phase 2b cohort of PRISM wet AMD study and long-term durability data supporting 4D\u2013150 4FRONT global registration program | 4D molecular therapeutics [Internet]. [cited 2025 Feb 23]. Available from: https:\/\/ir.4dmoleculartherapeutics.com\/news-releases\/news-release-details\/4dmt-presents-positive-52-week-results-phase-2b-cohort-prism-wet\/"},{"key":"e_1_3_4_88_1","unstructured":"4DMT highlights robust and durable clinical activity for 4D\u2013150 and design of 4FRONT phase 3 program at 4D\u2013150 wet AMD development day | 4D molecular therapeutics [Internet]. [cited 2024 Nov 3]. Available from: https:\/\/ir.4dmoleculartherapeutics.com\/news-releases\/news-release-details\/4dmt-highlights-robust-and-durable-clinical-activity-4d-150-and\/"},{"key":"e_1_3_4_89_1","unstructured":"L.ferguson@neurotechusa.com. Neurotech\u2019s ENCELTOTM (revakinagene taroretcel-lwey) approved by the FDA for the treatment of adults with idiopathic macular telangiectasia type 2 (MacTel) [Internet]. neurotech. 2025 [cited 2025 Apr 13]. Available from: https:\/\/www.neurotechpharmaceuticals.com\/neurotechs-enceltotm-revakinagene-taroretcel-lwey-approved-by-the-fda-for-the-treatment-of-macular-telangiectasia-type-2-mactel\/"},{"key":"e_1_3_4_90_1","unstructured":"Afshankhan1. English: illustration of the how the semi-permeable membrane works in cell microencapsulation. [Internet]. 2010 [cited 2024 Nov 30]. Available from: https:\/\/commons.wikimedia.org\/wiki\/File:Cell_capsule_schematic.png"},{"key":"e_1_3_4_91_1","unstructured":"onur. Neurotech pharmaceuticals announces positive phase 3 topline results for NT-501 implant in MacTel [Internet]. neurotech. 2022 [cited 2024 Nov 19]. Available from: https:\/\/www.neurotechpharmaceuticals.com\/neurotech-pharmaceuticals-announces-positive-phase-3-topline-results-for-nt-501-implant-in-mactel\/"},{"key":"e_1_3_4_92_1","unstructured":"Goldberg RA. MD: pooled visual function data of NT-501 for MacTel [internet]. HCP live. 2024 [cited 2024 Nov 20]. Available from: https:\/\/www.hcplive.com\/view\/roger-a-goldberg-md-pooled-visual-function-data-nt-501-mactel"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.846782"},{"issue":"7","key":"e_1_3_4_94_1","first-page":"2898","article-title":"Suprachoroidal delivery of suspensions of tyrosine kinase inhibitor, complement inhibitor, and corticosteroid: preclinical and clinical correlates","volume":"61","author":"Goldstein DA","year":"2020","unstructured":"Goldstein DA, Ciulla TA. Suprachoroidal delivery of suspensions of tyrosine kinase inhibitor, complement inhibitor, and corticosteroid: preclinical and clinical correlates. Invest Ophthalmol Visual Sci. 2020;61(7):2898.","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.1111\/aos.14042"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2021.0090"},{"issue":"7","key":"e_1_3_4_97_1","first-page":"4925","article-title":"Pharmacokinetics and ocular tolerability of suprachoroidal CLS-AX (axitinib injectable suspension) in rabbits","volume":"61","author":"Muya L","year":"2020","unstructured":"Muya L, Kansara V, Ciulla T. Pharmacokinetics and ocular tolerability of suprachoroidal CLS-AX (axitinib injectable suspension) in rabbits. Invest Ophthalmol Visual Sci. 2020;61(7):4925.","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.10.7.19"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.01.006"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2021.1954199"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-317560"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0953"},{"key":"e_1_3_4_103_1","unstructured":"Inc AB. Aura biosciences reports positive phase 2 end of study results evaluating bel-sar as a first-line treatment for early-stage choroidal melanoma [internet]. GlobeNewswire news room. 2024 [cited 2024 Nov 3]. Available from: https:\/\/www.globenewswire.com\/news-release\/2024\/09\/12\/2945023\/0\/en\/Aura-Biosciences-Reports-Positive-Phase-2-End-of-Study-Results-Evaluating-Bel-sar-as-a-First-Line-Treatment-for-Early-Stage-Choroidal-Melanoma.html"},{"key":"e_1_3_4_104_1","unstructured":"Aura biosciences reports Third Quarter 2024 financial results and business highlights - aura biosciences [Internet]. [cited 2024 Nov 14]. Available from: https:\/\/ir.aurabiosciences.com\/news-releases\/news-release-details\/aura-biosciences-reports-third-quarter-2024-financial-results\/"},{"key":"e_1_3_4_105_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11164717"},{"key":"e_1_3_4_106_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00487-6"},{"key":"e_1_3_4_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2013.03.137"},{"key":"e_1_3_4_108_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng0501-92"},{"key":"e_1_3_4_109_1","doi-asserted-by":"publisher","DOI":"10.3390\/genes15060720"},{"key":"e_1_3_4_110_1","unstructured":"Results posted | safety and tolerability of RGX-314 (investigational product) gene therapy for neovascular AMD trial | ClinicalTrials.Gov [Internet]. [cited 2024 Jan 18]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT03066258?tab=results"},{"key":"e_1_3_4_111_1","unstructured":"Study details | pivotal 1 study of RGX-314 gene therapy in participants with nAMD | ClinicalTrials.Gov [Internet]. [cited 2024 Jan 18]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04704921"},{"key":"e_1_3_4_112_1","unstructured":"Study details | pivotal 2 study of RGX-314 gene therapy in participants with nAMD | ClinicalTrials.Gov [Internet]. [cited 2024 Jan 18]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05407636"},{"key":"e_1_3_4_113_1","unstructured":"REGENXBIO announces updated strategic plans and Third Quarter 2023 financial results | Regenxbio inc [Internet]. [cited 2024 Jan 18]. Available from: https:\/\/regenxbio.gcs-web.com\/news-releases\/news-release-details\/regenxbio-announces-updated-strategic-plans-and-third-quarter\/"},{"key":"e_1_3_4_114_1","unstructured":"REGENXBIO announces positive interim data from phase II AAVIATE\u00ae trial of ABBV-RGX-314 for the treatment of wet AMD using suprachoroidal delivery | regenxbio inc [Internet]. [cited 2024 Jan 17]. Available from: https:\/\/regenxbio.gcs-web.com\/news-releases\/news-release-details\/regenxbio-announces-positive-interim-data-phase-ii-aaviater\/"},{"key":"e_1_3_4_115_1","unstructured":"Optireach Technology & Scientific Approach for Eye Drop Drug [Internet]. Oculis. [cited 2024 Nov 19]. Available from: https:\/\/oculis.com\/our-innovation\/science\/"},{"key":"e_1_3_4_116_1","doi-asserted-by":"publisher","DOI":"10.1111\/aos.15215"},{"key":"e_1_3_4_117_1","unstructured":"Oculis | oculis accelerates enrollment in both DIAMOND phase 3 trials of OCS-01 in diabetic macular edema and expands its DIAMOND program committees [Internet]. [cited 2024 Nov 19]. Available from: https:\/\/investors.oculis.com\/news-releases\/news-release-details\/oculis-accelerates-enrollment-both-diamond-phase-3-trials-ocs-01\/"},{"key":"e_1_3_4_118_1","unstructured":"Topical Delivery of Retinal Drugs [Internet]. PentaVision. [cited 2024 Nov 19]. Available from: https:\/\/www.retinalphysician.com\/issues\/2015\/september\/topical-delivery-of-retinal-drugs\/"},{"key":"e_1_3_4_119_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-4835(03)00213-6"},{"key":"e_1_3_4_120_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.117.10.1329"},{"key":"e_1_3_4_121_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2008.10.018"},{"key":"e_1_3_4_122_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S174573"},{"key":"e_1_3_4_123_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2010.08.002"},{"key":"e_1_3_4_124_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2011.08.038"},{"key":"e_1_3_4_125_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0190-15.2015"},{"key":"e_1_3_4_126_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100858"},{"issue":"8","key":"e_1_3_4_127_1","first-page":"1954","article-title":"Elamipretide protects RPE and Improves mitochondrial function in models of AMD","volume":"58","author":"Kapphahn R","year":"2017","unstructured":"Kapphahn R, Terluk M, Ebeling M, et al. Elamipretide protects RPE and Improves mitochondrial function in models of AMD. Invest Ophthalmol Visual Sci. 2017;58(8):1954.","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"e_1_3_4_128_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2021.100095"},{"key":"e_1_3_4_129_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2021.100086"},{"key":"e_1_3_4_130_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2024.100628"},{"key":"e_1_3_4_131_1","unstructured":"Stealth BioTherapeutics announces first patient enrolled in global phase 3 clinical program for elamipretide in patients with dry age-related macular degeneration - stealth BioTherapeutics inc. [Internet]. 2024 [cited 2024 Nov 18]. Available from: https:\/\/stealthbt.com\/stealth-biotherapeutics-announces-first-patient-enrolled-in-global-phase-3-clinical-program-for-elamipretide-in-patients-with-dry-age-related-macular-degeneration\/"},{"key":"e_1_3_4_132_1","unstructured":"Study details | ReNEW: Phase 3 study of efficacy safety & pharmacokinetics of subcutaneous injections of elamipretide in subjects with dry age-related macular degeneration (dry AMD) | ClinicalTrials.Gov [Internet]. [cited 2024 Nov 18]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06373731"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2025.2496424","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T03:03:52Z","timestamp":1748833432000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2025.2496424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,11]]},"references-count":130,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,5,24]]}},"alternative-id":["10.1080\/14656566.2025.2496424"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2025.2496424","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-11-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}